ID 13369
Sort Key
4
FullText URL
Thumnail 118_205.pdf 3.56 MB
Author
道上 宏之 Kakenhi
富澤 一仁
魏 范研
松下 正之
陸 雲飛
田宮 隆
Keywords
プロテインセラピー
悪性脳腫瘍
p 53
エンドソーム
蛋白導入ドメイン
Note
平成17年度岡山医学会賞(山田賞)受賞論文
Publication Title
岡山医学会雑誌
Published Date
2007-01-04
Volume
volume118
Issue
issue3
Publisher
岡山医学会
Publisher Alternative
Okayama Medical Association
Start Page
205
End Page
208
ISSN
00301558
NCID
AN00032489
Content Type
Journal Article
OAI-PMH Set
岡山大学
language
日本語
Copyright Holders
Copyright© 岡山医学会
File Version
publisher
Refereed
True
DOI
NAID
Eprints Journal Name
joma
References
1) DeAngelis LM: N Engl J Med (2001) 344, 114-123.
2) DeAngelis LM: N Engl J Med (2005) 352, 1036-1038.
3) ESGT: French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). J Gene Med (2003) 5, 82-84.
4) T Reid, R Warren, D Kim: Intravascular adenoviral agents in cancer patients: lessons from clinical traials. Cancer Gene Ther (2002) 9, 979-986.
5) R Vile, D Ando, D Kirn: The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider. Cancer Gene Ther (2002) 9, 1062-1067.
6) J Sodroski, R Patarca, C Rosen, F Wong-Staal, S Haseltine: Location of the trans-activating region on the geneme of human T-cell lymphotophic virus type III. Science (1985) 229, 74-77.
7) M Green, P Loewenstein: Autonomous functional domains of chemically synthesized human immunodeficiency virus Tat trans-activator protein. Cell (1988) 55, 1179-1188.
8) A Franckel, C Pabo: Cellular uptake of the Tat protein from human immunodeficiency virus. Cell (1988) 55, 1189-1193.
9) D Mann, A Frankel: Endocytosis and Targeting of exogenous HIV-1 Tat protein. EMBO J (1991) 10, 1733-1739.
10) S Fawell, J Seery, Y Daikh, C Moore, L Chen, B Pepinsky and J Barsoum: Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA (1994) 91, 664-668.
11) H Nagahara, AM Vocero-Akbani, EL Snyder, A Ho, DG Latham, NA Lissy, M Becker-Hapak, SA Ezhevsky and SF Dowdy: Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kipl induces cell migration. Nat Med (1998) 4, 1449-1452.
12) A Phelan, G Elliot and P O'Hare: Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol (1998) 16 (1998), 440-443.
13) A Joliot, C Pernelle, H Deagostini-Bazin and A Prochiantz: Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci USA (1991) 88, 1864-1868.
14) Matsushita M, Tomizawa K, Moriwaki A, Li ST, Terad H, Matsui H: A high-efficiency protein transduction system demonstrating the role of PKA in long-lasting longterm potentiation. J Neurosci (2001) 21 (16), 6000-6007.
15) Wadia JS, Stan RV, Dowdy SF: Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med (2004) 10 (3), 310-315.
16) Takenobu T, Tomizawa K, Matsushita M, Li ST, Moriwaki A, Lu YF, Matsui H: Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol Cancer Ther (2002) 1 (12), 1043-1049.
17) Michiue H, Tomizawa K, Wei FY, Matsushita M, Lu YF, Ichikawa T, Tamiya T, Date I, Matsui H: The NH2 terminus of influenza virus hemagglutinin-2 subunit peptides enhances the antitumor potency of polyargininemediated p53 protein transduction. J Biol Chem (2005) 280 (9), 8285-8289.
18) Michiue H, Tomizawa K, Matsushita M, Tamiya T, Lu YF, Ichikawa T, Date I, Matsui H: Ubiquitination-resistant p53 protein transduction therapy facilitates anti-cancer effect on the growth of human malignant glioma cells. FEBS Lett (2005) 579 (18), 3965-3969.
19) Snyder EL, Meade BR, Saenz CC, Dowdy SF: Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol (2004) 2 (2).
20) Fulda S, Wick W, Weller M, Debatin KM: Nat Med (2002) 8, 808-815.
21) Hosotani R, Miyamoto Y, Fujimoto K, et al.: Trojan pl6peptide suppresses pancreatic cancer growth and prolongs survival in mice. Clin Cancer Res (2002) 8, 1271-1276.
22) Borsello T, Clarke PGH, Hirt L, et al.: A peptide inhibitor of c-Jun N terminal kinase protects against excitoxicity and cerebral ischemia. Nat Med (2003) 9, 1180-1186.
23) Aarts M, Liu Y, Liu L, et al.: Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science (2002) 298, 846-850.
24) Myou S, Leef Ar, Myo S, et al.: Blockade of inflammation and airway hyperresponsiveness in immune-senssitized mice by dominant-negaive phosphoinositide 3-kinase-TAT. J Exp Med (2003) 198 (10), 1573-1582.
25) Clohisy Jc, Roy BC, Biondo C, et al.: Direct Inhibition of NF-kB Blocks Bone Erosion associated with inflammatory arthritis. J Immunolo (2003) 171 (10), 5547-5553.